Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gil Blum

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of the American Chemical Society|October 10, 2012
Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2Weihong Zheng, Glorymar Ibáñez, Hong Wu, et al.
Elife|May 14, 2019
The dynamic conformational landscape of the protein methyltransferase SETD8Shi Chen, Rafal P Wiewiora, Fanwang Meng, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of the American Chemical Society|October 10, 2012
Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2Weihong Zheng, Glorymar Ibáñez, Hong Wu, et al.
Elife|May 14, 2019
The dynamic conformational landscape of the protein methyltransferase SETD8Shi Chen, Rafal P Wiewiora, Fanwang Meng, et al.
Nature Medicine|October 6, 2015
Loss of BAP1 function leads to EZH2-dependent transformationLindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Nature Medicine|June 9, 2016
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status"Lindsay M LaFave, Wendy Béguelin, Richard Koche, et al.
Pageof 2